Phospho-PRKAR2B (Ser114) Antibody

What is PRKAR2B and what is the significance of its Ser114 phosphorylation?

PRKAR2B (also known as PKA-R2 beta, RIIβ) is one of four regulatory subunits of cAMP-dependent protein kinase (PKA), specifically the type II-beta regulatory subunit. The phosphorylation at Serine 114 occurs with formation of the PKA/RIIβ holoenzyme inhibitory state and affects PKA inhibition potency. Research shows that phospho-mimetic S114D mutation of RIIβ reduced PKA inhibition potency over 4-fold (IC₅₀ = 1.5 ± 0.3 nM for wild-type vs. 6.1 ± 1.1 nM for S114D mutant) . This phosphorylation is crucial for regulating PKA activity in response to various cellular signals.

How does PRKAR2B Ser114 phosphorylation differ from other regulatory subunit phosphorylations?

Unlike the pseudosubstrate regulatory subunit RIα, which is not degraded in certain conditions, RIIβ contains a substrate sequence that can be phosphorylated at Ser114. This phosphorylation appears to be linked to protein stability, as studies have shown that RIIβ phosphorylation levels decreased upon PKA activation with 8-Br-cAMP, suggesting that RIIβ phosphorylation might be associated with its degradation . Additionally, unlike other PKA regulatory subunit phosphorylation sites, Ser114 is located proximal to the inhibitor sequence in Type II R subunits and is specifically affected by phosphorylation at other sites like Thr69 .

What are the common experimental techniques used to detect Phospho-PRKAR2B (Ser114)?

Several techniques are commonly employed:

• Western blotting: The primary method, with COS7 cells often used as a positive control

• Immunohistochemistry (IHC): For detection in tissue sections, both paraffin-embedded and frozen

• Immunofluorescence (IF): For cellular localization studies

• Immunoprecipitation (IP): To study protein-protein interactions involving phosphorylated PRKAR2B

How is PRKAR2B Ser114 phosphorylation regulated by other phosphorylation events?

Research indicates a complex interplay between different phosphorylation sites on PRKAR2B. Notably, phosphorylation at Thr69 by Cdk5 directly influences Ser114 phosphorylation. The T69D phospho-mimetic mutation attenuates the efficiency of Ser114 phosphorylation by PKA, significantly reducing the maximum velocity of the reaction under linear conditions . This creates a reciprocal regulation mechanism where phospho-Thr69 levels inversely correlate with phospho-Ser114 levels, as demonstrated in studies using Cdk5 inhibitors and NMDA treatment in striatal brain slices .

What is the role of PRKAR2B Ser114 phosphorylation in neurotransmission integration?

Phosphorylation at Ser114 appears to be a critical molecular mechanism by which glutamatergic and dopaminergic signaling integrate to regulate PKA activity. Studies in ventral striatal slices show that NMDA treatment reduces phospho-Thr69 and increases phospho-Ser114, which affects PKA activity particularly when combined with dopamine stimulation . This integration mechanism may be crucial for striatal plasticity, as NMDA and dopamine receptor activation are essential to the induction of striatal LTP (Long-Term Potentiation), with sustained elevation of PKA activity observed 30 minutes after combined treatment .

How does PRKAR2B Ser114 phosphorylation contribute to disease pathophysiology?

Several disease connections have been identified:

Cushing's Syndrome: Mutations in PRKACA (encoding PKA catalytic subunit α) found in cortisol-producing adrenocortical adenomas affect RIIβ binding and stability. Specifically, the L206R mutation in PRKACA leads to RIIβ degradation that is dependent on Ser114 phosphorylation, mediated by caspase 16. This degradation increases cortisol secretion in adrenocortical cells, contributing to Cushing's syndrome pathophysiology .

Castration-Resistant Prostate Cancer (CRPC): PRKAR2B has been identified as overexpressed in CRPC. Functional validation experiments showed that PRKAR2B promotes CRPC cell proliferation and invasion while inhibiting apoptosis. The phosphorylation status at Ser114 may be involved in these processes, though the exact mechanism requires further investigation .

What are the key considerations when selecting an appropriate Phospho-PRKAR2B (Ser114) antibody?

When selecting an antibody, researchers should consider:

• Antibody type and species reactivity: Different antibodies (monoclonal vs. polyclonal) have varying specificities. For example:

  • Rabbit polyclonal antibodies (like AF3952 and PA537787) detect phospho-PRKAR2B in human, mouse, and rat samples

  • Mouse monoclonal antibodies (like pS114.20A) offer high specificity but may have more limited species reactivity

• Validated applications: Ensure the antibody is validated for your specific application:

  • Western Blot: PA537787 and sc-293036 are validated for this application

  • IHC: AF3952 is specifically validated for immunohistochemistry

  • IF/ICC: Some antibodies are specifically validated for immunofluorescence

• Phosphorylation specificity: Confirm the antibody specifically detects the phosphorylated form at Ser114 and not total PRKAR2B or other phosphorylation sites.

What controls should be included when using Phospho-PRKAR2B (Ser114) antibodies in experimental settings?

Proper controls are essential for reliable results:

• Positive controls:

  • COS7 cells are suggested as positive controls for Western blot

  • Brain tissue, particularly striatal slices, show detectable levels of phospho-Ser114 RIIβ

  • PKA activation with 8-Br-cAMP affects phosphorylation levels and can serve as a treatment control

• Negative controls:

  • RIIβ S114A mutant (where Ser114 is mutated to alanine) can serve as a negative control for phosphorylation

  • Adjacent white matter in brain tissue shows minimal staining compared to neurons

  • Samples treated with phosphatases to remove phosphorylation

• Validation controls:

  • Phospho-mimetic mutants (S114D) can help validate functional effects

  • Pharmacological modulators of PKA activity to demonstrate specificity

How can phospho-specific signal be distinguished from non-specific binding in Phospho-PRKAR2B (Ser114) antibody applications?

To ensure signal specificity:

• Peptide competition assays: Pre-incubate the antibody with the phosphopeptide used as immunogen (derived from human PKA-R2-beta around the phosphorylation site of Ser114)

• Phosphatase treatment: Treat one sample with lambda phosphatase to remove phosphorylation and compare to untreated samples

• Kinase/phosphatase modulators: Compare samples treated with PKA activators (increases phosphorylation) or phosphatase activators (decreases phosphorylation)

• Mutant constructs: Compare wild-type PRKAR2B with S114A mutant expression to demonstrate specificity

How does the integration of glutamatergic and dopaminergic signaling through PRKAR2B phosphorylation impact synaptic plasticity?

Research indicates a compound mechanism in which phospho-Thr69 levels on RIIβ are high under basal conditions. Glutamatergic neurotransmission via NMDA receptors reduces phospho-Thr69 through protein phosphatase activation (particularly PP2B/calcineurin), resulting in increased PKA-dependent phosphorylation of Ser114 RIIβ . When this occurs in conjunction with dopamine receptor activation, it leads to sustained elevated PKA activity affecting downstream effectors known to mediate synaptic plasticity (like phospho-Ser845 GluA1 and Thr34 DARPP-32) . This mechanism may be particularly important in striatal functions and plasticity, with peptide inhibitors targeting Thr69 phosphorylation enhancing cortico-ventral striatal plasticity by increasing PKA activity and AMPAR-mediated function .

What is the relationship between PRKAR2B Ser114 phosphorylation and protein stability in disease contexts?

In the context of certain PKA catalytic subunit mutations (like L206R in PRKACA), Ser114 phosphorylation appears to be required for RIIβ degradation, mediated by caspase 16 . This degradation has functional consequences, such as increased cortisol secretion in adrenocortical cells related to Cushing's syndrome . The molecular mechanism involves changes in protein interactions, with proteomic analyses showing differential binding partners for RIIβ in the presence of mutant catalytic subunits. For example, Golgin A3 was identified to bind RIIβ only in the presence of the Cα L206R mutant . This suggests that phosphorylation at Ser114 may affect not only RIIβ stability but also its interaction network, potentially explaining diverse functional outcomes in different disease contexts.

How might targeting PRKAR2B Ser114 phosphorylation be exploited therapeutically?

Based on current research, several therapeutic approaches could be considered:

• Neurological disorders: Since Ser114 phosphorylation regulates PKA activity important for synaptic plasticity, compounds modulating this phosphorylation could potentially address disorders involving dysregulated synaptic plasticity. The RIIβ siP (signaling interference peptide) targeting Thr69 phosphorylation (which indirectly affects Ser114 phosphorylation) showed enhanced cortico-ventral striatal plasticity and increased AMPAR-mediated function , suggesting potential for treating conditions with impaired plasticity.

• Endocrine disorders: In Cushing's syndrome caused by PRKACA mutations, preventing RIIβ degradation by inhibiting Ser114 phosphorylation might reduce pathological cortisol secretion .

• Cancer therapy: Given PRKAR2B's oncogenic role in castration-resistant prostate cancer , targeting its phosphorylation status could potentially affect cancer cell proliferation, invasion, and survival. Understanding how Ser114 phosphorylation influences PRKAR2B's regulation of cell cycle genes (CCNB1, MCM2, PLK1, AURKB) could lead to novel therapeutic strategies.

Table 1: Comparison of Commercial Phospho-PRKAR2B (Ser114) Antibodies

Table 2: Functional Relationships Between PRKAR2B Phosphorylation Sites

Table 3: Experimental Conditions for Studying PRKAR2B Ser114 Phosphorylation